Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02989974
Other study ID # 17-BS-01
Secondary ID 16-0813
Status Completed
Phase N/A
First received
Last updated
Start date February 10, 2017
Est. completion date April 24, 2019

Study information

Verified date October 2020
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the Kentucky LEADS Lung Cancer Survivorship Care Program is to develop, administer and evaluate the impact of a comprehensive psychosocial survivorship care program for individuals diagnosed with lung cancer and their caregivers to improve lung cancer survivorship and delivery of high-quality lung cancer care. The investigators hypothesize that the Kentucky LEADS Lung Cancer Survivorship Care Program will demonstrate improved quality of life, better symptom control, increased tobacco treatment, and reduced distress among lung cancer survivors and their caregivers.


Description:

The study design is a single-arm clinical trial, or a prospective cohort design, where a longitudinal series of data will be collected from participants. Participants will be consented and asked to complete a baseline questionnaire (PRE) which includes topics measuring quality of life, distress, symptom management, social support, healthy behaviors, demographics and health history. Two similar questionnaires will be administered after exposure to the Survivorship Care Program (POST and FOL). In addition, the consent form requests permission from survivors to collect clinical data from medical records and the Kentucky Cancer Registry regarding diagnosis and treatment for lung cancer. The study will enroll 300 participants, with an estimate of approximately 30 participants enrolled at each site. However, if a participating site enrolls 30 participants and the overall study accrual has not yet been met, the study PI may allow that respective participating site to continue to enroll participants. Study accrual is competitive across participating sites until the overall study accrual has been met.


Recruitment information / eligibility

Status Completed
Enrollment 214
Est. completion date April 24, 2019
Est. primary completion date April 24, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Individuals who have been diagnosed with lung cancer (survivor) or - Caregiver of a participating lung cancer survivor - Ability to read and write in English Exclusion Criteria: - Individuals with significant psychiatric disturbance that requires a higher level of care - Individuals with substance abuse/dependence problem that require a higher level of care - Incarcerate individuals or individuals detained within the legal system

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
KY LEADS Survivorship Care
Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment. Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment

Locations

Country Name City State
United States Kings Daughters Medical Center - Ashland Ashland Kentucky
United States Commonwealth Cancer Center - Danville Danville Kentucky
United States Hardin Memorial Health - Elizabethtown Elizabethtown Kentucky
United States Hazard ARH Regional Medical Center Hazard Kentucky
United States Markey Cancer Center Lexington Kentucky
United States UofL/Brown Cancer Center - Louisville Louisville Kentucky
United States Baptist Health - Madisonville Madisonville Kentucky
United States St. Claire Regional Medical Center - Morehead Morehead Kentucky
United States Owensboro Health Owensboro Kentucky

Sponsors (4)

Lead Sponsor Collaborator
Jamie Studts Bristol-Myers Squibb Foundation, Lung Cancer Alliance, University of Louisville

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Tertiary Study Feasibility A: Questionnaire 2 survey completion rate by survivors Study Feasibility - Survivor survey completion rate (3A) 1 week post-intervention up to 1 month post-intervention
Other Tertiary Study Feasibility B: Study drop-out rate among participating survivors Study Feasibility - Survivor drop-out rate (3B) 1 week post-intervention up to 1 month post-intervention
Other Tertiary Study Feasibility C: Rate of missing survivor/caregiver data Study Feasibility - Rate of missing survivor/caregiver data (3C) 1 week post-intervention up to 1 month post-intervention
Other Additional Study Efficacy A1: Survivor quality of life Study Efficacy - Impact on survivor quality of life (FACT-G) (4A1) 1 week post-intervention up to 1 month post-intervention
Other Additional Study Efficacy B1: Survivor lung cancer specific quality of life Study Efficacy - Impact on survivor lung cancer specific quality of life (FACT-L) (4B1) 1 week post-intervention up to 1 month post-intervention
Other Additional Study Efficacy A2: Caregiver quality of life tudy Efficacy - Impact on caregiver quality of life (C-QoL) (4A2) 1 week post-intervention up to 1 month post-intervention
Other Additional Study Efficacy B2: Caregiver self-efficacy Study Efficacy - Impact on caregiver self-efficacy (CSES) (4B2) 1 week post-intervention up to 1 month post-intervention
Primary Primary Survivor Acceptability A: Percentage of participating survivors that would recommend the program to other survivors on POST survey Participating survivor intervention acceptability (1A) 1 week post-intervention up to 1 month post-intervention
Primary Primary Survivor Acceptability B: Mean rating of participating survivor intervention satisfaction on POST survey Participating survivor intervention satisfaction (1B) 1 week post-intervention up to 1 month post-intervention
Primary Primary Survivor Acceptability C: Percentage of planned intervention modules completed by participating survivors based on SC Specialists intervention delivery tracking data Participating survivor intervention uptake (1C) 1 week post-intervention up to 1 month post-intervention
Secondary Secondary Intervention Feasibility A: Intervention accrual rate Intervention Feasibility - study accrual rate (2A) 6 months post-baseline
Secondary Secondary Intervention Feasibility B: Survivorship Care (SC) Specialist ratings of intervention feasibility based on SC Specialist ratings on POST survey Intervention Feasibility - SC Specialist ratings (2B) 6 months post-baseline
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk